Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JD.Com Inc (JD) vs TransMedics Group Inc (TMDX) Price & Performance

JD.Com IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

JD.Com Inc vs TransMedics Group Inc — how do they compare? JD.Com Inc trades at $31.76 (market cap $44.04B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: JD.Com Inc is far larger — about 14.2× TransMedics Group Inc's market cap, and JD.Com Inc pays a 3.13% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

JDTMDX
Market Cap
$44.04B$3.10B
Sector
Consumer CyclicalTechnology
52-Week High
$36.17$150.42
52-Week Low
$25.19$61.99
Enterprise Value
$30.10B$3.49B
Dividend Yield
3.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JD.Com Inc

JD.com trades at $31.46, down 6.01% over 24 hours, with technical indicators showing bullish momentum despite recent pressure. The company reported strong Q1 2026 earnings of $0.74 EPS, beating expectations by 30%, while revenue grew to $1.31 trillion in 2025. Analysts maintain a bullish consensus with 32 buy ratings and a $38.00 price target, representing 21% upside potential. Recent news highlights JD's upcoming Q2 earnings report on August 13, 2026, with expectations of 618 promotion benefits.

JD presents compelling value with a P/S ratio of 0.24 and consistent earnings beats, though net margins remain thin at 1.05%. Regulatory scrutiny of the Ceconomy acquisition and competitive pressures pose risks, but institutional accumulation and bullish technicals support further upside. The stock's current level near key support at $31 offers an attractive entry point ahead of Q2 results.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX